Research studying the probiotic strain GanedenBC30 (Bacillus coagulans GBI-30, 6086) found that it survives in efficacious amounts through the manufacturing and preparation of pasta. 
 
This study marks the 22nd study of the patented probiotic GanedenBC30 from Ganeden Biotech. It is now published in the Journal of Cereal Science.
 
The study, conducted by the University of Verona, developed pasta formulated with GanedenBC30 to analyze and highlight the health potential of a functional pasta. Results of the research, completed by using standard USP enumeration protocols, illustrated GanedenBC30 left the characteristics of the pasta unaffected and displayed survival in efficacious levels at both five and seven minute cook times.
 
“This study is exciting, as it shows the distinctive formulation capabilities of GanedenBC30 in an additional product category that would be impossible for traditional probiotics,” said Mike Bush, senior vice president of Ganeden. “This research not only continues to build on our library of science supporting GanedenBC30, but as a science driven company we are honored that the Italian Ministry of Health continues to choose GanedenBC30 for their studies; a collaboration which dates back to 2007.”
 
For more information: www.ganedenprobiotics.com